FDA Approves Rezdiffra for Nonalcoholic Steatohepatitis

FRIDAY, March 15, 2024 -- On Thursday, the U.S. Food and Drug Administration announced the approval of Rezdiffra (resmetirom) to treat noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate-to-advanced fibrosis. " Previously, patients with...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news